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Study-related covariates: analytical method used to quantify vancomycin (FPIA EMIT, 152 PENTINIA or CMIA CLIA), creatinine assay method (Jaffé or enzymatic) and 153 corresponding units. 154
Data analysis 155
PK data were made available on a standard Microsoft Office Excel spreadsheet (CIC, 156 1426, Hôpital Robert Debré) and formatted for subsequent modelling using NONMEM V 157
(Icon Development Solutions, USA). 158
A first order conditional estimation (FOCE) method with interaction was used to estimate 159 PK parameters and their variability. One and two compartment models with first order 160 elimination were tested to estimate clearance (CL), central volume of distribution (V1), 161 peripheral volume of distribution (V2) and intercompartmental clearance (Q) using the 162 appropriate ADVAN subroutines. Inter-individual variability of the pharmacokinetic 163 parameters was best described with an exponential model and was expressed as θi= 164 θmean*e ηi , where θi represents the parameter value of the i th subject, θmean the typical value 165 of the parameter in the population and ηi the variability between subjects, which is 166 assumed to follow a normal distribution with a mean of zero and variance ω 2 . 167
Covariate analysis followed a forward and backward selection process. The likelihood 168 ratio test was used to test the effect of each variable on model parameters. The effects 169 of current weight, gestational age, postnatal age, postmenstrual age, serum creatinine 170 concentration, analytical methods of vancomycin and creatinine, and ethnicity were 171 investigated as potential covariates affecting PK parameters. During the first step of 172 covariate model building, a covariate was included if a significant (p<0.05, 2 distribution 173 with one degree of freedom) decrease (reduction>3.84) in the objective function value 174 (OFV) from the basic model was obtained. All the significant covariates were then added 175 simultaneously into a 'full' model. Subsequently, each covariate was independently8 removed from the full model. If the increase in the OFV was higher than 6.635 (p<0.01, 177  2 distribution), the covariate was retained in the final model. (AUCSS-24h) were calculated for each simulated patient. The parameter estimates obtained 198 from the final model were used to estimate the target attainment rate for an AUC24h of 199 ≥400 mg*h/L with the standard dosage regimen recommended in the "Blue Book" 13 and 200 to define the optimal dosing regimen able to attain this target in 80% of patients. The 201 9 current dosage recommendations and a loading dose followed by a maintenance dose 202 administered as an intermittent infusion were evaluated in the 3 PMA groups. 203
204

Results
205
Study population. 206
A total of 1631 neonates and infants from 15 studies were included (Table 1) . Their PMA 207 and current weight (CW), expressed as mean (standard deviation) were 33.3 (5.7) weeks 208 and 1785 (1127) grams, respectively. Overview of the individual PK trials is presented in 209 Table 2 . We refer to the original studies for additional factual information. 14-26 210
211
Population PK analysis 212
Model building 213
A total of 4894 concentrations from 1631 patients were included in the population 214 analysis. A two-compartment model with first-order elimination best fitted the data; both 215 the OFV and the residual variability were lower than with a one-compartment model. 216
Covariate analysis 217
Allowing separate estimates for each analytical method in the residual variability caused 218 a significant drop in the OFV of 113.5 units. Body weight was the most important clinical 219 covariate following a systematic covariate analysis, associated with a drop in the OFV of 220 3367.1 units after incorporating it into the basic model using estimated allometric 221 coefficients for CL, V1 and V2. A further decrease in the OFV of 244.5 units was achieved 222 by including PMA on CL and serum creatinine concentrations gave a further reduction 223 (ΔOFV 1087.9 units). The model was further improved (ΔOFV 65.5 units) by introducing 224 a conversion factor between the Jaffé and enzymatic assay methods for creatinine. where CW is current weight, RM reflects renal maturation and RF reflects renal function. 229
The population PK parameters of the final model are presented in Table 3 . 230
Model evaluation 231
Model diagnostics showed acceptable goodness-of-fit for the final model. Predictions 232 were unbiased and no trends were observed in the diagnostic plots of CWRES versus 233 In addition, the median PK parameter estimates resulting from the bootstrap procedure 241 closely agreed with the respective values from the final population model, indicating that 242 the final model was stable (Table 3) . 243
Dosing optimisation. 244
Dosing optimisation was conducted in the Caucasian population. Monte Carlo simulations 245 were performed to evaluate different mg/kg dosing regimens for the three neonatal 246
groups. 247
With the standard vancomycin dosing regimen at steady-state, the percentage of 248 neonates reaching the target AUCss0-24 of ≥400 mg*h/ was 74.0% and the percentage 249 exposed to an AUCss0-24 above 700 mg*h/L was 23.0% when considering all age groups. 250
11
When considering only neonates <29 weeks PMA, the corresponding values fell to 27.7% 251 and 1.1% respectively (Table 4) . 252
With a loading dose of 25 mg/kg followed by the optimal maintenance dose of 15 mg/kg, 253 either 'q12h' if ≤35 weeks PMA or 'q8h' if >35 weeks PMA, the percentage of neonates 254 reaching the target AUCss0-24 of 400 mg*h/L was 89.3% while the percentage exposed to 255 an AUCss24h over 700 mg*h/L was 33.3% when considering all age groups. When 256 considering only neonates <29 weeks PMA, the corresponding values increased to 95.0% 257 and 45.5% respectively ( Table 5 ). The target attainment rate on the first day of treatment 258 increased from 42.6% with the standard regimen to 88.9% with the loading dose strategy. 259
260
Discussion 261
To the best of our knowledge, this is the largest meta-analysis that has assessed the 262 population PK of vancomycin in neonates and young infants aged less than 3 months. 263
The analysis has combined vancomycin concentrations linked to key demographic and 264 biological covariates from 15 pharmacokinetic studies conducted in 7 different countries. 265
Monte-Carlo simulations showed that the current dosage regimen was not suitable for the 266 treatment of staphylococcal infection and that the optimal vancomycin dosing regimen 267 should include a loading dose of 25 mg/kg for all neonates, irrespective of their PMA, 268 followed by a maintenance dose adapted to their PMA. 269
Although widely used for many years, important questions remain on how to optimise 270 vancomycin dosing in neonates. 2, 8, 9 In the absence of prospective evaluation, most 271 neonatal units have developed local dosing recommendations, resulting in variable 272 exposures that may lead to poor efficacy, induction of resistance or toxicity 3 273
Consequently, vancomycin dosage regimens adapted to neonates require harmonisation, 274 taking into account the impact of developmental pharmacology on disposition and PK 275 12 parameters from very preterm neonates through term neonates to older children. 27 This 276 issue is central and initiatives from both the FDA and EMA are currently being undertaken 277 to revise vancomycin dosing. 28 environmental and nutritional differences, were not explored in the current study, as they 288
were not available in all data sets. However, it is recognised that they may also contribute 289 to PK variability in neonates. 290
Model-based approaches to characterise drug PK/PD have been recommended as 291 powerful tools for overcoming the practical and ethical challenges associated with dose 292 selection for neonatal indications. 39, 40 For vancomycin, a model tailored dose had already 293 been demonstrated to increase substantially the target attainment rate of vancomycin in 294 treated neonates. 10 However, there were few neonates less than 29 weeks gestational 295 age in that study and centre-effects could not be eliminated. These limitations were 296 addressed in the present PK meta-analysis, which was conducted by pooling 4894 297 vancomycin concentrations from 1631 neonates. Although robust parameter estimates 298
were obtained with this strategy, different strategies may be necessary when data are 299 heterogenous. 41 independently, since the trough depends on both the daily dose and the frequency of 305 administration, whereas AUC0-24 only depends on the daily dose. Consequently, in the 306 present study, simulations were performed to evaluate the current dosage regimen 13 and 307 to optimize efficacy by determining the target attainment rate and exposure to vancomycin 308 measured by the AUC0-24h. A target AUC0-24h of at least 400 mg*h/L was selected as an 309 AUC0-24/MIC ratio of 400 has been associated with favourable treatment outcomes in 310 adults, assuming that bacterial strains have a vancomycin MIC ≤1 mg/L. 43, 46 Simulations 311 of the current dosage recommendation (see table 5) were performed after the first dose 312 and at steady-state. Our results showed that the current daily dose was too low for all 313 neonatal age groups but particularly for neonates <29 weeks, as less than 30% of 314 neonates reached the steady-state target. As a loading dose strategy is recommended in 315 adult settings in order to reduce the time needed to reach the target AUC0-24 47,48 316 simulations were then performed with a loading dose and optimal maintenance doses in 317 all age groups, based on weight and PMA. Increasing the maintenance dose to 15 mg/kg 318 'q12h' instead of 'q24h' was also tested in the group <29 PMA weeks to optimise dosage. 319
These modifications led to an increase in the target attainment rate after the first dose 320 and at steady-state in all age groups. 321
Nephrotoxicity is a recognized side-effect of vancomycin treatment, although its safety 322 profile is considered favorable. The risk of nephrotoxicity primarily increases with high 323 vancomycin exposure and duration of administration. 45, 49 In studies in adults and 324 children, 45 reported incidence varied widely, from 5% to 43%, occurrence increased with 325
powered to detect nephrotoxicity and, when reported, renal impairment was frequently 328 associated with concomitant administration of nephrotoxic drugs. 50 329 Therefore, optimising exposure while reducing duration of administration would maximise 330 clinical efficacy while minimising toxicity and selection of resistance. 331
The upper AUC24h limit remains a matter of debate. "Usual" AUC24h values of 700 or 800 332 mg*h/L have been used in both adults 46,51,52 and children, 48 however, more extreme 333 values have also been reported, with breakpoints for nephrotoxicity of <600 or >1300 334 mg*h/L. 51, 53 In the absence of specific neonatal data, a value of 700 mg*h/L was used in 335 the present study. With our simulated dosage regimen, 89% of neonates reached the 336 predetermined AUCss-24h target and 21.0% had an AUCss-24h, over 800 mg*h/L; this was 337 slightly higher that the percentage expected with the dosing regimen that is currently 338 used. Additional TDM is necessary to individualise therapy for patients at risk of high 339 exposure rates. 340
The simulated drug regimens presented here in the different neonatal age groups 341 
